Meta Expands AI Training With Employee Activity Tracking Tools 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
SK Hynix Reports Record Q1 Profit Surge Driven by AI Memory Chip Demand 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
NEW YORK, March 17, 2017 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of Aratana Therapeutics, Inc securities (NASDAQ:PETX) from March 16, 2015 through February 3, 2017, inclusive (the “Class Period”) of the important April 7, 2017 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Aratana investors under the federal securities laws.
To join the Aratana class action, go to http://rosenlegal.com/cases-1049.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) Aratana did not have manufacturing contracts in place sufficient to support manufacturing of ENTYCE at a commercial scale; (2) consequently, ENTYCE was not likely to be commercially available until late 2017; (3) accordingly, Aratana had misled investors with respect to the likely timeline for a commercial launch of ENTYCE; and (4) as a result, Aratana’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 7, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://rosenlegal.com/cases-1049.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com
